Highly Potent Non-Viral Drug Delivery Nanosystems
OZ Biosciences has developed a Microfluidics Platform for the reproducible development of safe & potent drug delivery vehicles for pharmaceutical applications.
Our platform can produce custom LNP according to your needs and preferences.
Custom LNP service workflow
Our team is dedicated in providing you with high quality LNP that will meet your project needs. You can provide your own molecule of interest to encapsulate or we can make a custom mRNA for you.
We can support every stage of your mRNA-LNP production, from mRNA synthesis to LNP formulation development, manufacturing and fill & finish.
For any of RNA, DNA or APIs encapsulation, you can provide us with your molecule of interest and we will formulate it into LNPs.
Our expert product support team is at your service for your special requests - you are invited to reach out to our experts to discuss your needs.
NanOZ-LNPs are formulated through pressure-driven controlled flow microfluidics systems. Once collected and purified, NanOZ-LNPs physico-chemical properties are fully characterized in terms of size distribution, charge surface, structure integrity, encapsulation efficiency and stability.
The NanOZ-LNP/mRNA are monodisperse nanoparticles of spherical morphology with size usually ranging between 80-150nm and PDI<0.2. Once encapsulated, the integrity of the mRNA is verified by gel electrophoresis.
Fig. 1: Physico-chemical characterizations of NanOZ-LNP/mRNA: Size distribution and Polydispersity Index measurements by DLS, morphology and monodispersity observed by colour negative SEM and CryoTEM micrographies and mRNA integrity after formulation inside LNP monitored by agarose gel electrophoresis at mRNA dose equals to 0.5µg. Data Source: The results obtained by OZB, Marseille.
The biodistribution and transfection efficiency of NanOZ-LNP loaded with Firefly Luciferase mRNA (mRNA-Luc) was evaluated after i.p. injection of 10µg mRNA formulated in LNP in nude mice with two formulations based on proprietary ionizable lipids compared with a LNP formulation based on DOTAP cationic lipid. Bioluminescence intensity was monitored by IVIS instrument over 25h.
As observed in Figure 2, a single intra-peritoneal (i.p.) injection of Luc-LNPs enables high bioluminescence signal and luciferase expression into surrounded organs for at least 25h (Figure 4). The highest transfection efficiency was observed for the NanOZ-LNP1 formulation.
Fig. 2: IVIS images 6h after i.p. administration of 3 mRNA-LNPs formulation: NanOZ-LNP1, NanOZ-LNP2 and DOTAP-LNP in nude mice. Kinetics of bioluminescence signal over 25h after i.p. administration of 3 mRNA-LNPs formulation: NanOZ-LNP1, NanOZ-LNP2 and DOTAP-LNP in nude mice (dose equivalent to 10µg mRNA). Data Source: The results were acheived in collaboration with the TRACE PDX Platform, KU Leuven.
The comparison between mRNA-based vaccines versus subunit vaccine for immune efficacy were evaluated in C57BL6J mice using the ovalbumin model. Prime boost (D0-14) immunizations were evaluated with OVA antigen delivered by mRNA-based LNPs, where two different formulations were tested corresponding to LNP1 and LNP2, or by recombinant protein (alone or adjuvanted). To characterize the immuno-phenotyping of the mice the sera were collected at D0, D14, D21 and D28 and splenocytes were collected at D28 and analysed by ELISA, Elispot and Multiplex. The mice were immunized by s.c. route with 10µg OVA subunit (SU) or 10µg mRNA doses (100µL per injection).
RNA vaccine LNP formulations are efficient at priming a strong Th1 humoral response equivalent to the best TH1 adjuvants such as QS-21 upon sub-cutaneous prime boost injection (D0-14) in C57BL6J mice. In addition, no significative signal was observed when the OVA antigen is directly administrated. It is noteworthy, the necessity of two injections (boost at D14) to obtain a long-lasting immune response.
Fig. 3: Anti-OVA IgG production and Th1 humoral biomarker to OVA subunit vaccine (10µg) in absence or presence of vaccines adjuvants (QS21 (5µg), Alum (Aluminum Hydroxide gel)1X or addaVax 1X) and to mRNA(OVA)-LNPs (mRNA dose equals to 10µg) upon sub-cutaneous prime boost injection (D0-14) in C57BL6J mice. Data Source: The results were acheived by OZ Biosciences in collaboration with Dr. Antoine Tanne, SaponiQx, Lexington, MA, USA
Data show that LNP carrying mRNA can be used for transfecting cells in vitro but with less efficiency than classic transfection reagents such as RmesFect: at least 10 times more material would be needed using LNP. Depending on the cell line (such as JurKat T cells cultivated in suspension) LNP could be an alternative to transfection reagents for genetic modification with a very high efficiency; however, the fluorescence intensity that could account for the number of delivered molecule is still below.
Figure 4: In vitro transfection using LNP and Lipoplexes. (A) HeLa cells cultivated in 24-well plates were transfected with ranging doses of mRNA (from 0.1 µg to 10µg) encoding for GFP encapsulated with LNP1 and LNP2. (B) HeLa cells were transfected with 0.125 and 0.25µg mRNA encoding for GFP complexed to RmesFect transfection reagent using two ratios, 3:1 and 4:1 (respectively 3µL and 4µL per µg mRNA). GFP expression in (A) and (B) was monitored by fluorescence microscopy 48H after transfection. (C) Jurkat T cells were transfected using ranging doses of mRNA encapsulated with LNP1 and LNP2 or complexed with RmesFect (ratio 3:1). 48H after transfection, percentage of transfected cells (left graph) and fluorescence intensity (right graph) were determined by flow cytometry.
Download LNP In Vitro resultsDownload LNP In Vivo Results
Technical Resources
- LNP Stability Note - Download
- White Paper : Ionizable lipids for mRNA-LNP and siRNA-LNP - Read
- LNP F.A.Q - Read
Custom LNP F.A.Q
You can easily request a quote by filling in our dedicated form available here. If you need further guidance or wish to discuss your project and specific requirements with our technical team, feel free to contact us — we will be happy to arrange a meeting at your convenience.
Once the mRNA or nucleic acid cargo is ready, our LNP production process typically takes 2 to 3 weeks: approximately one week for production and one week for quality control. If custom mRNA synthesis is also required, please allow an additional 8 weeks for mRNA production prior to LNP formulation.
The minimum order quantity for our custom LNP formulation service is 0.5 mL. For specific requirements outside this range, please contact us to discuss available options.
Our custom LNP formulation service supports encapsulation of a wide range of molecules, including mRNA, siRNA, saRNA, DNA, ASO/ODN, and other molecules of interest. Regarding the origin of the cargo, we offer three options:
- OZB catalog mRNA: choose from our existing catalog of ready-to-use mRNAs (e.g. GFP, Luciferase, OVA, Spike).
- OZB custom mRNA: we produce a custom mRNA from your sequence of interest.
- Customer-supplied molecule: you provide your own molecule, which we will encapsulate into our LNP system.
Simply indicate your preferences when filling in our dedicated custom LNP formulation quote form and our team will get back to you with a tailored proposal.
Yes. As part of our custom service, we can work with alternative ionizable lipids or entirely different LNP compositions to meet your specific delivery requirements; whether for targeted delivery, specialized routes of administration, or unique cargo types. If you are able to provide your own lipids, we can incorporate them into our formulation process. Simply specify this when filling in our custom LNP formulation quote form and we will proceed accordingly.
Yes, the final concentration can be modulated upon request. However, achievable concentrations may vary depending on the nature and amount of the encapsulated molecule. Please specify your concentration requirements when submitting your order or quote request.
Yes. As an option, our LNPs can be functionalized with targeting ligands such as peptides or antibodies, enabling active targeting strategies for specific cell types or tissues. Please contact us or fill in our custom LNP formulation quote form to discuss the feasibility for your application.
Each LNP batch undergoes a comprehensive quality control workflow including particle size and PDI measurement by DLS, zeta potential analysis, encapsulation efficiency determination by fluorescent assay, and mRNA concentration measurement. The sterility is also assessed by incubating the LNPs in culture medium for 14 days. For superior grade products, endotoxin testing and cholesterol content quantification are additionally performed.
Please refer to our LNP quoting tool to select the QC level that best fits your project requirements.
Discover our other custom services
Custom mRNA Synthesis Service
OZ Biosciences offers mRNAs that mimic fully processed mature mRNAs.
These mRNAs are stabilized with 5’ Cap 1 structure and 3’ poly(A) tail and are...
Custom saRNA Synthesis Service
Self-amplifying RNAs (saRNAs) also called “Replicons” are the next generation of RNA vaccines.
Their advantage over conventional mRNA vaccine platforms relies on the viral replication machinery,...